Embarking on a Fulbright research endeavor, I aim to address the formidable challenges in treating aggressive brain tumors. My focus is on developing personalized nanomedicines using an innovative hitchhiking strategy, offering a novel approach to overcome the unique complexities of these conditions.
Amirali, an Associate Professor and Director of Research at the School of Pharmacy, University of Queensland, is making ground-breaking strides in the field of nanomedicine with a focus on developing personalized treatments for chronic diseases like Diabetes, Cancer, and Inflammatory Disorders.
Amirali’s Fulbright research at the Wyss Institute, Harvard University will involve the development and validation of hitchhiking ultrasmall nanoparticles, a pioneering approach aimed at overcoming biological barriers to effectively treat brain cancers. Adding to the significance of this endeavor is Amirali’s mentorship by Prof. Samir Mitragotri, a world-renowned scientist specialising in drug delivery.